Table 1 Randomized controlled trials of chemoprevention
Drug | First author | Year | Prevention drug | Study design | Patient characteristics | Total patient number | Number of patients given drug | Number of patients given placebo | Follow up(months) | Development of BC | Development of IDC | Development of DCIS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
TAM | Bernard Fisher | 2005 | Placebo vs TAM 20mg(5years) | Randomized controlled trial | >60 years or between 35 and 59 years with high risk of BC, or a history of LCIS or atypical hyperplasia | 13388 | 6681 | 6707 | 74 | Â | RR; 0.57 (95% CI: 0.46-0.7) | RR 0.63 (95% CI; 0.45-0.89) |
Jack Cuzick | 2014 | Placebo vs TAM 20mg(5years) | Randomized controlled trial | 35–70 years with high risk of BC | 7154 | 3579 | 3575 | 192 | HR; 0.71 (95% CI: 0.6-0.83) |  |  | |
Powles TJ | 2007 | Placebo vs TAM 20mg(8years) | Randomized controlled trial | 30-70 years with high risk of BC | 2471 | 1238 | 1233 | 158 | HR 0.84 (95% CI; 0.64-1.1) | HR 0.78 (95% CI; 0.58-1.04) | - | |
Umberto Veronesi | 2007 | Placebo vs TAM 20mg(5years) | Randomized controlled trial | 35–70 years with high risk of BC | 5408 | 2708 | 2700 | 109 | HR; 0.84 (95% CI: 0.6-1.17) |  |  | |
Raloxifene | J A Cauley | 2001 | Placebo vs Raloxifene 60mg vs 120mg | Randomized controlled trial | postmenopausal women with osteoporosis and no history of BC | 7705 | 2557(60mg), 2572(120mg) | 2576 | 40 | Â | RR 0.28 (95% CI; 0.17-0.46) | Â |
Silvana Mrtino | 2004 | Placebo vs Raloxifene 60mg | Randomized controlled trial | postmenopausal women with osteoporosis and no history of BC | 4011 | 2725 | 1286 | 96 | HR 0.42 (95% CI; 0.29-0.6) | HR 0.34 (95% CI; 0.22-0.5) | Â | |
Elizabeth Barrett-Connor | 2006 | Placebo vs Raloxifene 60mg | Randomized controlled trial | postmenopausal women with CHD or multiple risk factors for CHD | 10101 | 5044 | 5057 | 66 | HR 0.67 (95% CI; 0.47-0.89) | HR 0.56 (95% CI; 0.38-0.83) | HR 2.17 (95% CI; 0.75-6.24) | |
Exemestane | Paul E. Goss | 2011 | Placebo vs Exemestane | Randomized controlled trial | >60 years with high risk of BC, or a history of DCIS, LCIS, atypical ductal or lobular hyperplasia | 4560 | 2285 | 2275 | 35 | HR 0.47 (95% CI; 0.27-0.79) | HR 0.35 (95% CI; 0.18-0.7) | HR 0.65 (95% CI; 0.28-1.51) |
Anastrozole | Jack Cuzick | 2014 | Placebo vs Anastrozole | Randomized controlled trial | 40–70 years with high risk of BC | 3851 | 1914 | 1937 | 60 | HR 0.47 (95% CI; 0.32-0.68) | HR 0.5 (95% CI; 0.32-0.76) | HR 0.3 (95% CI; 0.12-0.74) |